About Eli Lilly and Company
Eli Lilly and Company (LLY) is a Healthcare company in the Pharmaceutical Preparations industry with a market capitalisation of $1.1T. The stock trades at 42.75x trailing earnings and yields 0.54%.
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Market cap
- $1.1T
- P/E ratio
- 42.75
- Forward P/E
- 26.97
- EPS (TTM)
- $29.79
- Revenue (TTM)
- $79.7B
- Free cash flow
- $11.1B
- Profit margin
- 33.5%
- Dividend yield
- 0.54%
- Beta
- 0.45
- Shares outstanding
- 891.4M
Financial health: Strong8.3/10
7 strengths, 1 concern. Weakest points: debt to equity.
- Debt to equity: 1.60 (Concern, benchmark < 0.5) — Debt of 1.60x equity is high against the 0.5x benchmark. It has been broadly flat over the last 4 years.
- Current ratio: 1.58 (Strong, benchmark > 1.5) — Short-term assets cover 1.58x short-term liabilities, against Graham's 1.5x floor. It has improved over the last 4 years.
- Return on equity: 102.3% (Strong, benchmark > 15%) — Earns 102.3% on shareholder equity, comfortably past the > 15% mark.
- Gross margin: 83.4% (Strong, benchmark > 40%) — Keeps 83.4% of revenue after the direct cost of sales, comfortably past the > 40% mark.
- Net margin: 33.5% (Strong, benchmark > 10%) — Turns 33.5% of revenue into profit, comfortably past the > 10% mark.
- Revenue growth: 47.7% (Strong, benchmark > 10%) — Revenue changed 47.7% year on year, comfortably past the > 10% mark.
- Earnings growth: 26.2% (Strong, benchmark > 10%) — Earnings changed 26.2% year on year, comfortably past the > 10% mark.
- PEG ratio: 1.16 (Watch, benchmark < 1) — At 1.16, the price looks fair relative to expected growth — Lynch treated 1.0 as fair value.
- Payout ratio: 21.7% (Strong, benchmark < 60%) — Pays out 21.7% of earnings as dividends, leaving room to keep paying.